// App-Quantinova.ai

Su1053 : Virological Response in Treatment-NaiVE Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon ?-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Researchers

Presenter

  • Donald M. Jensen

Principal Investigators

  • Daniel Genne

  • Kelly Kaita

  • Andreas Maieron

  • Liliana Preotescu

  • Christoph Sarrazin

  • Elmar Zehnter

  • Adrian Streinu-Cercel

  • Jerry O. Stern

  • Yakov Datsenko

  • Murray Drulak

  • Mark Sulkowski

  • Florian Voss

  • Anne-Marie Quinson

  • Peter Ferenci

  • Denis Ouzan

  • Luis Morano

  • Robert Buynak

  • Kosh Agarwal

  • Tarek Hassanein

  • Daniel Forton

  • Mong Cho

Medical Centers

  • Hopital Beaujon, APHP, University Paris-Diderot and INSERM CRB, Clichy, France

  • Guy's Hospital, London, United Kingdom

  • Institut Arnault Tzanck, St Laurent du Var, France

  • Schwerpunktpraxis Hepatologie, Dortmund, Germany

  • Elizabethan Hospital, Linz, Austria

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Hospital Do Meixoeiro, Vigo, Spain

  • Northwest Indiana Center for Clinical Research, Valparaiso, IN

  • Southern California Liver Centers, Coronado, CA

  • Chaux de Fonds Hospital, Chaux de Fonds, Switzerland

  • Queen Mary University of London, London, United Kingdom

  • University of Mantioba, Winnipeg, MB, Canada

  • The University of Chicago Medical Center, Chicago, IL

  • Kings College London, London, United Kingdom

  • Medical University of Vienna, Vienna, Austria

  • Goethe University, Frankfurt, Germany

  • Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases Prof. Dr. Matei Bals, Bucharest, Romania

Locations

  • Canada

  • Austria

  • Germany

  • Spain

  • United Kingdom

  • Switzerland

  • United States

  • France

  • Romania

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Interferon

Drug/Treatment

  • Faldaprevir-sodium

  • Interferon

  • Ribavirin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved